New findings from the ECOG-ACRIN EA4151 Phase 3 trial, published in Blood on November 25, 2024, could change clinical practice for mantle cell lymphoma (MCL).
For years, autologous hematopoietic cell transplantation (auto-HCT) has been a standard approach in first complete remission (CR). However, this large randomized study found no added survival benefit for patients achieving undetectable minimal residual disease (uMRD) questioning the need for auto-HCT in this group.
Key insights from EA4151:
Patients in first CR with uMRD did not benefit from auto-HCT
Those who remained MRD-positive post-induction may still gain from transplant.
Results align with recent TRIANGLE trial data, reinforcing the evolving treatment landscape.
This trial reshapes how MCL is managed, emphasizing a shift toward more tailored approaches based on MRD status. Longer follow-up will be crucial to validate these findings.
A major appreciation to the researchers behind this pivotal study your work continues to drive innovation in lymphoma treatment.
Read more in: https://lnkd.in/eCWX7fNa
